Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.

Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, Foster CS, Affeldt J, Seedor JA, Afshari NA, Chao W, Allegretti M, Mantelli F, Dana R.

Ophthalmology. 2020 Jan;127(1):14-26. doi: 10.1016/j.ophtha.2019.08.020. Epub 2019 Aug 26.

2.

DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain.

Brandolini L, Castelli V, Aramini A, Giorgio C, Bianchini G, Russo R, De Caro C, d'Angelo M, Catanesi M, Benedetti E, Giordano A, Cimini A, Allegretti M.

Sci Rep. 2019 Aug 13;9(1):11729. doi: 10.1038/s41598-019-48231-z.

3.

Correction: Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis.

Cassano M, Biressi S, Finan A, Benedetti L, Omes C, Boratto R, Martin F, Allegretti M, Broccoli V, Cusella De Angelis G, Comoglio PM, Basilico C, Torrente Y, Michieli P, Cossu G, Sampaolesi M.

PLoS One. 2019 Jul 24;14(7):e0220357. doi: 10.1371/journal.pone.0220357. eCollection 2019.

4.

Chemokine Signaling in Chemotherapy-Induced Neuropathic Pain.

Brandolini L, d'Angelo M, Antonosante A, Allegretti M, Cimini A.

Int J Mol Sci. 2019 Jun 14;20(12). pii: E2904. doi: 10.3390/ijms20122904. Review.

5.

Correction to: The Novel C5aR Antagonist DF3016A Protects Neurons Against Ischemic Neuroinflammatory Injury.

Brandolini L, Grannonico M, Bianchini G, Colanardi A, Sebastiani P, Paladini A, Piroli A, Allegretti M, Varrassi G, Di Loreto S.

Neurotox Res. 2019 Aug;36(2):439. doi: 10.1007/s12640-019-00049-3.

6.

The Novel C5aR Antagonist DF3016A Protects Neurons Against Ischemic Neuroinflammatory Injury.

Brandolini L, Grannonico M, Bianchini G, Colanardi A, Sebastiani P, Paladini A, Piroli A, Allegretti M, Varrassi G, Di Loreto S.

Neurotox Res. 2019 Jul;36(1):163-174. doi: 10.1007/s12640-019-00026-w. Epub 2019 Apr 5. Erratum in: Neurotox Res. 2019 May 6;:.

7.

Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study.

Sacchetti M, Lambiase A, Schmidl D, Schmetterer L, Ferrari M, Mantelli F, Allegretti M, Garhoefer G.

Br J Ophthalmol. 2020 Jan;104(1):127-135. doi: 10.1136/bjophthalmol-2018-312470. Epub 2019 Apr 3.

8.

An ESCRT-LEM protein surveillance system is poised to directly monitor the nuclear envelope and nuclear transport system.

Thaller DJ, Allegretti M, Borah S, Ronchi P, Beck M, Lusk CP.

Elife. 2019 Apr 3;8. pii: e45284. doi: 10.7554/eLife.45284.

9.

Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).

Finotti A, Allegretti M, Gasparello J, Giacomini P, Spandidos DA, Spoto G, Gambari R.

Int J Oncol. 2018 Oct;53(4):1395-1434. doi: 10.3892/ijo.2018.4516. Epub 2018 Aug 6. Review.

10.

Bayesian inference of rotor ring stoichiometry from electron microscopy images of archaeal ATP synthase.

Cossio P, Allegretti M, Mayer F, Müller V, Vonck J, Hummer G.

Microscopy (Oxf). 2018 Oct 1;67(5):266-273. doi: 10.1093/jmicro/dfy033.

PMID:
30032235
11.

A Child with a c.6923_6928dup (p.Arg2308_Met2309dup) SPTAN1 Mutation Associated with a Severe Early Infantile Epileptic Encephalopathy.

Rapaccini V, Esposito S, Strinati F, Allegretti M, Manfroi E, Miconi F, Pitzianti M, Prontera P, Principi N, Pasini A.

Int J Mol Sci. 2018 Jul 6;19(7). pii: E1976. doi: 10.3390/ijms19071976.

12.

Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA).

Gasparello J, Allegretti M, Tremante E, Fabbri E, Amoreo CA, Romania P, Melucci E, Messana K, Borgatti M, Giacomini P, Gambari R, Finotti A.

J Exp Clin Cancer Res. 2018 Jun 26;37(1):124. doi: 10.1186/s13046-018-0788-1.

13.

Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating EWS-FLI1 fusion transcripts.

Allegretti M, Casini B, Mandoj C, Benini S, Alberti L, Novello M, Melucci E, Conti L, Covello R, Pescarmona E, Milano GM, Annovazzi A, Anelli V, Ferraresi V, Biagini R, Giacomini P.

Ther Adv Med Oncol. 2018 Jun 1;10:1758835918774337. doi: 10.1177/1758835918774337. eCollection 2018.

14.

Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.

Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W, Mantelli F; REPARO Study Group.

Ophthalmology. 2018 Sep;125(9):1468-1471. doi: 10.1016/j.ophtha.2018.03.004. Epub 2018 Apr 10. No abstract available.

15.

Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.

Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, Mantelli F; REPARO Study Group.

Ophthalmology. 2018 Sep;125(9):1332-1343. doi: 10.1016/j.ophtha.2018.02.022. Epub 2018 Apr 10.

16.

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.

Allegretti M, Fabi A, Buglioni S, Martayan A, Conti L, Pescarmona E, Ciliberto G, Giacomini P.

J Exp Clin Cancer Res. 2018 Mar 5;37(1):47. doi: 10.1186/s13046-018-0702-x.

17.

Antinociceptive effect of two novel transient receptor potential melastatin 8 antagonists in acute and chronic pain models in rat.

De Caro C, Russo R, Avagliano C, Cristiano C, Calignano A, Aramini A, Bianchini G, Allegretti M, Brandolini L.

Br J Pharmacol. 2018 May;175(10):1691-1706. doi: 10.1111/bph.14177. Epub 2018 Apr 14.

18.

Intravital Microscopic Evaluation of the Effects of a CXCR2 Antagonist in a Model of Liver Ischemia Reperfusion Injury in Mice.

de Oliveira THC, Marques PE, Poosti F, Ruytinx P, Amaral FA, Brandolini L, Allegretti M, Proost P, Teixeira MM.

Front Immunol. 2018 Jan 5;8:1917. doi: 10.3389/fimmu.2017.01917. eCollection 2017.

19.

CXCR1/2 Antagonism Is Protective during Influenza and Post-Influenza Pneumococcal Infection.

Tavares LP, Garcia CC, Machado MG, Queiroz-Junior CM, Barthelemy A, Trottein F, Siqueira MM, Brandolini L, Allegretti M, Machado AM, de Sousa LP, Teixeira MM.

Front Immunol. 2017 Dec 13;8:1799. doi: 10.3389/fimmu.2017.01799. eCollection 2017.

20.

CXCR2 is critical for bacterial control and development of joint damage and pain in Staphylococcus aureus-induced septic arthritis in mouse.

Boff D, Oliveira VLS, Queiroz Junior CM, Silva TA, Allegretti M, Verri WA Jr, Proost P, Teixeira MM, Amaral FA.

Eur J Immunol. 2018 Mar;48(3):454-463. doi: 10.1002/eji.201747198. Epub 2018 Jan 9.

21.

Differential protein modulation by ketoprofen and ibuprofen underlines different cellular response by gastric epithelium.

Brandolini L, d'Angelo M, Antonosante A, Villa S, Cristiano L, Castelli V, Benedetti E, Catanesi M, Aramini A, Luini A, Parashuraman S, Mayo E, Giordano A, Cimini A, Allegretti M.

J Cell Physiol. 2018 Mar;233(3):2304-2312. doi: 10.1002/jcp.26102. Epub 2017 Aug 25.

PMID:
28710861
22.

CXCR1/2 pathways in paclitaxel-induced neuropathic pain.

Brandolini L, Benedetti E, Ruffini PA, Russo R, Cristiano L, Antonosante A, d'Angelo M, Castelli V, Giordano A, Allegretti M, Cimini A.

Oncotarget. 2017 Apr 4;8(14):23188-23201. doi: 10.18632/oncotarget.15533.

23.

Multiple anti-tumor effects of Reparixin on thyroid cancer.

Liotti F, De Pizzol M, Allegretti M, Prevete N, Melillo RM.

Oncotarget. 2017 May 30;8(22):35946-35961. doi: 10.18632/oncotarget.16412.

24.

Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.

Kemp DM, Pidich A, Larijani M, Jonas R, Lash E, Sato T, Terai M, De Pizzol M, Allegretti M, Igoucheva O, Alexeev V.

Oncotarget. 2017 Feb 28;8(9):14428-14442. doi: 10.18632/oncotarget.14803.

25.

Conformational Change in the Mechanism of Inclusion of Ketoprofen in β-Cyclodextrin: NMR Spectroscopy, Ab Initio Calculations, Molecular Dynamics Simulations, and Photoreactivity.

Guzzo T, Mandaliti W, Nepravishta R, Aramini A, Bodo E, Daidone I, Allegretti M, Topai A, Paci M.

J Phys Chem B. 2016 Oct 20;120(41):10668-10678. doi: 10.1021/acs.jpcb.6b07913. Epub 2016 Oct 11.

PMID:
27689813
26.

Allosteric Modulation of Chemoattractant Receptors.

Allegretti M, Cesta MC, Locati M.

Front Immunol. 2016 May 2;7:170. doi: 10.3389/fimmu.2016.00170. eCollection 2016. Review.

27.

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).

Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, Garasa S, Fusco JP, Aznar A, Inogés S, De Pizzol M, Allegretti M, Medina-Echeverz J, Berraondo P, Perez-Gracia JL, Melero I.

Clin Cancer Res. 2016 Aug 1;22(15):3924-36. doi: 10.1158/1078-0432.CCR-15-2463. Epub 2016 Mar 8.

28.

Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, Torrisi MR, Tafuri A.

Sci Rep. 2016 Feb 5;6:20743. doi: 10.1038/srep20743. No abstract available.

29.

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, Torrisi MR, Tafuri A.

Sci Rep. 2015 Dec 17;5:18137. doi: 10.1038/srep18137. Erratum in: Sci Rep. 2016;6:20743.

30.

DF2755A, a novel non-competitive allosteric inhibitor of CXCR1/2, reduces inflammatory and post-operative pain.

Lopes AH, Brandolini L, Aramini A, Bianchini G, Silva RL, Zaperlon AC, Verri WA Jr, Alves-Filho JC, Cunha FQ, Teixeira MM, Allegretti M, Cunha TM.

Pharmacol Res. 2016 Jan;103:69-79. doi: 10.1016/j.phrs.2015.11.005. Epub 2015 Nov 28.

31.

DFL23448, A Novel Transient Receptor Potential Melastin 8-Selective Ion Channel Antagonist, Modifies Bladder Function and Reduces Bladder Overactivity in Awake Rats.

Mistretta FA, Russo A, Castiglione F, Bettiga A, Colciago G, Montorsi F, Brandolini L, Aramini A, Bianchini G, Allegretti M, Bovolenta S, Russo R, Benigni F, Hedlund P.

J Pharmacol Exp Ther. 2016 Jan;356(1):200-11. doi: 10.1124/jpet.115.228684. Epub 2015 Nov 6.

PMID:
26546575
32.

Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.

Brandolini L, Cristiano L, Fidoamore A, De Pizzol M, Di Giacomo E, Florio TM, Confalone G, Galante A, Cinque B, Benedetti E, Ruffini PA, Cifone MG, Giordano A, Alecci M, Allegretti M, Cimini A.

Oncotarget. 2015 Dec 22;6(41):43375-94. doi: 10.18632/oncotarget.6234.

33.

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A.

Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156.

34.

Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias.

Ricciardi MR, Mirabilii S, Allegretti M, Licchetta R, Calarco A, Torrisi MR, Foà R, Nicolai R, Peluso G, Tafuri A.

Blood. 2015 Oct 15;126(16):1925-9. doi: 10.1182/blood-2014-12-617498. Epub 2015 Aug 14.

PMID:
26276667
35.

Clinical presentation and outcome of patients with ST-segment elevation myocardial infarction without culprit angiographic lesions.

Zhu T, Huitema A, Alemayehu M, Allegretti M, Chomicki C, Yadegari A, Lavi S.

Cardiovasc Revasc Med. 2015 Jun;16(4):217-20. doi: 10.1016/j.carrev.2015.04.004. Epub 2015 Apr 20.

PMID:
25940686
36.

Horizontal membrane-intrinsic α-helices in the stator a-subunit of an F-type ATP synthase.

Allegretti M, Klusch N, Mills DJ, Vonck J, Kühlbrandt W, Davies KM.

Nature. 2015 May 14;521(7551):237-40. doi: 10.1038/nature14185. Epub 2015 Feb 23.

PMID:
25707805
37.

Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief.

Moriconi A, Cunha TM, Souza GR, Lopes AH, Cunha FQ, Carneiro VL, Pinto LG, Brandolini L, Aramini A, Bizzarri C, Bianchini G, Beccari AR, Fanton M, Bruno A, Costantino G, Bertini R, Galliera E, Locati M, Ferreira SH, Teixeira MM, Allegretti M.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16937-42. doi: 10.1073/pnas.1417365111. Epub 2014 Nov 10.

38.

CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice.

Citro A, Valle A, Cantarelli E, Mercalli A, Pellegrini S, Liberati D, Daffonchio L, Kastsiuchenka O, Ruffini PA, Battaglia M, Allegretti M, Piemonti L.

Diabetes. 2015 Apr;64(4):1329-40. doi: 10.2337/db14-0443. Epub 2014 Oct 14.

39.

Gastroprotective effects of L-lysine salification of ketoprofen in ethanol-injured gastric mucosa.

Cimini A, Brandolini L, Gentile R, Cristiano L, Menghini P, Fidoamore A, Antonosante A, Benedetti E, Giordano A, Allegretti M.

J Cell Physiol. 2015 Apr;230(4):813-20. doi: 10.1002/jcp.24809.

PMID:
25287669
40.

Atomic model of the F420-reducing [NiFe] hydrogenase by electron cryo-microscopy using a direct electron detector.

Allegretti M, Mills DJ, McMullan G, Kühlbrandt W, Vonck J.

Elife. 2014 Feb 25;3:e01963. doi: 10.7554/eLife.01963.

41.

Production of fully assembled and active Aquifex aeolicus F1FO ATP synthase in Escherichia coli.

Zhang C, Allegretti M, Vonck J, Langer JD, Marcia M, Peng G, Michel H.

Biochim Biophys Acta. 2014 Jan;1840(1):34-40. doi: 10.1016/j.bbagen.2013.08.023. Epub 2013 Sep 1.

PMID:
24005236
42.

CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.

Citro A, Cantarelli E, Maffi P, Nano R, Melzi R, Mercalli A, Dugnani E, Sordi V, Magistretti P, Daffonchio L, Ruffini PA, Allegretti M, Secchi A, Bonifacio E, Piemonti L.

J Clin Invest. 2012 Oct;122(10):3647-51. doi: 10.1172/JCI63089. Epub 2012 Sep 17.

43.

Current status of chemokine receptor inhibitors in development.

Allegretti M, Cesta MC, Garin A, Proudfoot AE.

Immunol Lett. 2012 Jul 30;145(1-2):68-78. doi: 10.1016/j.imlet.2012.04.003. Epub 2012 Apr 20. Review.

PMID:
22698186
44.

Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer.

Zacchetti A, Martin F, Luison E, Coliva A, Bombardieri E, Allegretti M, Figini M, Canevari S.

J Nucl Med. 2011 Dec;52(12):1938-46. doi: 10.2967/jnumed.110.086819. Epub 2011 Nov 8.

45.

Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.

Moriconi A, Bigogno C, Bianchini G, Caligiuri A, Resconi A, Dondio MG, D'Anniballe G, Allegretti M.

ACS Med Chem Lett. 2011 Aug 7;2(10):768-73. doi: 10.1021/ml2001533. eCollection 2011 Oct 13.

46.

Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.

Bertini R, Barcelos LS, Beccari AR, Cavalieri B, Moriconi A, Bizzarri C, Di Benedetto P, Di Giacinto C, Gloaguen I, Galliera E, Corsi MM, Russo RC, Andrade SP, Cesta MC, Nano G, Aramini A, Cutrin JC, Locati M, Allegretti M, Teixeira MM.

Br J Pharmacol. 2012 Jan;165(2):436-54. doi: 10.1111/j.1476-5381.2011.01566.x.

47.

Spontaneous protein crowding in liposomes: a new vista for the origin of cellular metabolism.

Luisi PL, Allegretti M, Pereira de Souza T, Steiniger F, Fahr A, Stano P.

Chembiochem. 2010 Sep 24;11(14):1989-92. doi: 10.1002/cbic.201000381. No abstract available.

PMID:
20806308
48.

LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells.

Sturla L, Fresia C, Guida L, Bruzzone S, Scarfì S, Usai C, Fruscione F, Magnone M, Millo E, Basile G, Grozio A, Jacchetti E, Allegretti M, De Flora A, Zocchi E.

J Biol Chem. 2009 Oct 9;284(41):28045-57. doi: 10.1074/jbc.M109.035329. Epub 2009 Aug 10.

49.

Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.

Sablone MR, Cesta MC, Moriconi A, Aramini A, Bizzarri C, Di Giacinto C, Di Bitondo R, Gloaguen I, Aschi M, Crucianelli M, Bertini R, Allegretti M.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. doi: 10.1016/j.bmcl.2009.06.027. Epub 2009 Jun 13.

PMID:
19560921
50.

Development and validation of an LC-MS/MS method for determination of methanesulfonamide in human urine.

Anacardio R, Mullins FG, Hannam S, Sheikh MS, O'Shea K, Aramini A, D'Anniballe G, D'Anteo L, Ferrari MP, Allegretti M.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):2087-92. doi: 10.1016/j.jchromb.2009.05.051. Epub 2009 Jun 17.

PMID:
19539545

Supplemental Content

Loading ...
Support Center